Frontiers in Pediatrics (Sep 2022)

Procalcitonin at 12–36 hours of fever for prediction of invasive bacterial infections in hospitalized febrile neonates

  • Anne-Sophie Romain,
  • Romain Guedj,
  • Romain Guedj,
  • Anais Chosidow,
  • Nicolas Mediamolle,
  • Aurélie Schnuriger,
  • Aurélie Schnuriger,
  • Sophie Vimont,
  • Sophie Vimont,
  • Charlène Ferrandiz,
  • Nicolas Robin,
  • Marie-Hélène Odièvre,
  • Marie-Hélène Odièvre,
  • Emmanuel Grimprel,
  • Mathie Lorrot

DOI
https://doi.org/10.3389/fped.2022.968207
Journal volume & issue
Vol. 10

Abstract

Read online

AimWe aimed to investigate the performance of procalcitonin (PCT) assay between 12 and 36 h after onset of fever (PCT H12-H36) to predict invasive bacterial infection (IBI) (ie, meningitis and/or bacteremia) in febrile neonates.MethodsWe retrospectively included all febrile neonates hospitalized in the general pediatric department in a teaching hospital from January 2013 to December 2019. PCT assay ≤ 0.6 ng/ml was defined as negative. The primary outcome was to study the performance of PCT H12-H36 to predict IBI.ResultsOut of 385 included neonates, IBI was ascertainable for 357 neonates (92.7%). We found 16 IBI: 3 meningitis and 13 bacteremia. Sensitivity and specificity of PCT H12-H36 in the identification of IBI were, respectively, 100% [95% CI 82.9–100%] and 71.8% [95% CI 66.8–76.6%], with positive and negative predictive values of 14.3% [95% CI 8.4–22.2%] and 100% [95% CI 98.8–100%] respectively. Of the 259 neonates who had a PCT assay within the first 12 h of fever (< H12) and a PCT assay after H12-H36, 8 had IBI. Two of these 8 neonates had a negative < H12 PCT but a positive H12-H36 PCT.ConclusionsPCT H12-H36 did not miss any IBI whereas < H12 PCT could missed IBI diagnoses. PCT H12-H36 might be included in clinical decision rule to help physicians to stop early antibiotics in febrile neonates.

Keywords